Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration - Chen, Zi-Rong; Chueh, Chen-Han; Chiang, Nai-Jung; Tsai, Yi-Wen (Cost Effectiveness & Resource Allocation, 2023)